Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Lung Diseases 1Liposarcoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

Carboplatin 10Paclitaxel 5Nivolumab 4Pemetrexed 3Cisplatin 3atezolizumab 2apatinib 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Blood Specimen Collection 2Bevacizumab 2zimberelimab 1toripalimab 1spartalizumab 1sitravatinib 1sintilimab 1sacituzumab govitecan 1pembrolizumab 1lorlatinib 1cemiplimab 1camrelizumab 1Vital Signs 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Telescopes 1Talc 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Diseases × sitravatinib × Clear all
NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Yale University

Phase 2 Terminated
9 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡